MANE Form 4 reports acquisition/exercise transactions
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Carrano Dominic Gabriel reported acquisition or exercise transactions in a Form 4 filing for MANE. The filing lists transactions totaling 148,011 shares. Following the reported transactions, holdings were 148,011 shares.
Insider Trade Summary
Grant/Award: 148,011 shares
Grant/Award
1 txn
Insider
Carrano Dominic Gabriel
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 148,011 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 148,011 options (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 148,011 options (Direct)
Footnotes (1)
- F1. The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share, on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Veradermics (MANE) disclose in this Form 4 for its CFO?
Veradermics disclosed a stock option grant to its CFO. Dominic Gabriel Carrano received an option to buy 148,011 shares of common stock at a $17 exercise price, expiring February 3, 2036, with vesting over four years tied to his continued service.
What is the exercise price and term of the Veradermics (MANE) CFO option grant?
The option has a $17 exercise price and a 10-year term. The grant dated February 3, 2026 allows purchase of common stock at $17 per share and expires on February 3, 2036, giving a long-dated equity incentive period.
What is the vesting schedule for Dominic Gabriel Carrano’s Veradermics (MANE) option?
The option vests over four years with an initial cliff. Twenty-five percent vests on February 3, 2027, one year after the vesting commencement date. The remaining shares vest in equal monthly installments over the next 36 months, conditioned on continued service.
Is the Veradermics (MANE) CFO’s stock option held directly or indirectly?
The option is reported as directly owned. The Form 4 lists 148,011 derivative securities beneficially owned following the transaction with ownership form marked as “D” for direct, with no nature of indirect beneficial ownership specified.
What transaction code is used for the Veradermics (MANE) CFO option grant?
The transaction is coded as an “A” grant or award. The Form 4 classifies the February 3, 2026 stock option as a derivative acquisition, using transaction code A for a grant, award, or other acquisition, rather than an open-market purchase or sale.
AI-generated analysis. How Rhea-AI works. Not financial advice.